HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
GILD
Gilead Sciences Inc
Healthcare Drug Manufacturers - General · California, USA · Reports in usd
Market Cap: $181.42B
Market Cap
$181.42B
Enterprise Val
$204.49B
P/E Ratio
-55.99
P/B Ratio
15.34
Trailing PEG (1Y)
0.09
As Of
Aug 20, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value$11.74B
Gross Margin79.76%
Profit Margin79.76%
Return on Equity-16.28%
Return on Assets-5.81%
Current Ratio1.27
Debt/Equity2.22
LT Debt/Equity2.01
Revenue Per Share6.28

Income Statement

Jun 30, 2026
Revenue$7.80B
Cost of Revenue$1.58B
Gross Profit$6.22B
R&D$1.76B
SG&A$1.92B
Operating Expenses$16.62B
Operating Income-$10.39B
Interest Expense$247.0M
Tax Expense$242.0M
Net Income-$10.50B
EPS (Basic)$-8.45
EPS (Diluted)$-8.45
EBIT-$10.01B
EBITDA-$9.31B
Consolidated Income-$10.50B
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2026
Cash & Equivalents$3.18B
Accounts Receivable$5.06B
Inventory$1.95B
Current Assets$13.95B
LT Investments$0.00
Property, Plant & Equipment$5.83B
Intangibles$22.35B
Non-Current Assets$35.42B
Total Assets$49.36B
Accounts Payable$674.0M
Current Debt$2.41B
Current Liabilities$11.02B
LT Debt$23.83B
Non-Current Liabilities$26.60B
Total Liabilities$37.62B
Total Debt$26.25B
Retained Earnings$2.20B
Shareholder Equity$11.83B
Shares Outstanding1,241,569,874

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow$3.57B
Investing Cash Flow-$10.35B
Financing Cash Flow$2.34B
CapEx-$140.0M
Free Cash Flow$3.43B
Depreciation & Amort.$698.0M
Stock-Based Comp$231.0M
Acquisitions / Disposals-$11.21B
Investment Activity$983.0M
Debt Issued/Repaid$4.07B
Equity Issued/Repaid-$346.0M
Dividends Paid-$1.03B
Net Change in Cash-$4.45B
Data cached · Meta live · Daily live · Statements live · TTL 24h